Iovance Biotherapeutics Inc (NAS:IOVA)
$ 8.1 -0.04 (-0.49%) Market Cap: 2.27 Bil Enterprise Value: 2.02 Bil PE Ratio: 0 PB Ratio: 3.33 GF Score: 35/100

Iovance Biotherapeutics Inc Provides Update for Lifileucel in Metastatic Melanoma- Corporate Call Transcript

Oct 05, 2020 / 08:30PM GMT
Release Date Price: $32.06 (+1.78%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Iovance Biotherapeutics Regulatory Update. (Operator Instructions)

I will now hand the conference over to your speaker today, Ms. Sara Pellegrino. Please go ahead.

Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations

Thank you, operator. Good afternoon, and thank you for joining us. Speaking on today's call, we have Maria Fardis, our President and Chief Executive Officer. This afternoon, we issued a press release that can be found on our website at iovance.com, which includes a regulatory update.

Before we start, I would like to remind everyone that statements made during this conference call will include forward-looking statements regarding Iovance's goals, business focus, business plans, pre-commercial activities, clinical trial plans and results, potential future applications of our technologies, manufacturing capabilities, regulatory feedback and guidance, collaborations, cash position and expense guidance and future updates.

Forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot